Exogenous human albumin supplementation in total parenteral nutrition of critically ill newborns

Abstract

On the basis of the results obtained in the present study, no benefits were derived from the use of human albumin in total parenteral nutrition in severely ill newborns; therefore its use cannot be recommended, unless the objective is exclusively to elevate albumin levels.

Propensity‐Score Matched Comparative Study on Effects of Intravenous Human Serum Albumin Administration in Critically Ill Adult Patients Receiving Parenteral Nutrition

“…The administration of 25–30 g of IV HSA added to PN resulted in a serum albumin level increase in 12/13 (92.3%) patients, but in a decrease in prealbumin in 5/13 (38.5%) patients . In the aforementioned newborn study, final prealbumin was not different between the groups …”

“…In a case‐control study, the administration of 1 g/kg/day of IV HSA for 10 days in critically ill, preterm newborns receiving PN resulted in significant increases in serum albumin levels and plasma total proteins when compared with the newborns who did not receive IV HSA. However, calculated NAPP decreased ≈0.06 g/dL in newborns receiving IV HSA, but increased ≈0.44 g/dL in those who did not receive IV HSA . In a retrospective study in cats and dogs, the administration of IV HSA in a dose of 1.25 g/kg resulted in an increase in the serum albumin levels in all groups studied, but globulins (the main component of NAPP) decreased in 3 of the 5 groups studied, remained nearly stable in 1 group, and increased in another group.…”